Stay updated on ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC

Sign up to get notified when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.
Latest website image capture
Clouds background image

Latest updates to the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification in the clinical trial study details related to the evaluation of the efficacy and safety of Eribulin Mesylate in combination with Pembrolizumab for participants with Metastatic Triple-Negative Breast Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:39.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. This change clarifies the criteria used to determine participant eligibility for the study.
    Difference
    50%
    Check dated 2024-05-22T21:22:59.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:49:31.000Z thumbnail image

Stay in the know with updates to ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC

Enter your email address, and we'll notify you when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.